An interventional study of Bladder EpiCheck in Non-Muscle-Invasive Bladder Cancer, sponsored by Istituto Oncologico Veneto IRCCS. Not yet recruiting at 1 site in Italy. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Istituto Oncologico Veneto IRCCS · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Non-Muscle Invasive Bladder Neoplasms with a site in Italy — 12 open to participants now, 15 under way, 5 of them phase 3. Non-Muscle Invasive Bladder Neoplasms · Italy.
Among the 30 studies in Non-Muscle Invasive Bladder Neoplasms with a site in Italy, this one is the 21st largest by planned enrollment of the 27 interventional ones that give a count, is the only one that started in 2027, is one of 7 with no phase, reaches primary completion later than 11 of the 14 other live ones, and was the 30th registered.
294 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 126 are open to participants now.
Browse Non-Muscle Invasive Bladder Neoplasms studies →12 of the 30 studies in Non-Muscle Invasive Bladder Neoplasms with a site in Italy are open now. Recruiting first, the newest first:
University of Roma La Sapienza · Sites in Italy
Ages 18+
Janssen Research & Development, LLC · Sites in Italy, United States, Argentina and 12 more countries
Ages 18+
Tyra Biosciences, Inc · Sites in Italy, United States, Australia and 1 more country
Ages 18+
Merck Sharp & Dohme LLC · Sites in Italy, United States, Argentina and 16 more countries
Ages 18+
Istituto Oncologico Veneto IRCCS · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 93 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 78 (84%) set no upper age limit and 5 (5%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 8 · Phase 4 1
First in 1994; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 62 across 231 interventional studies indexed under Non-Muscle Invasive Bladder Neoplasms.
Median enrollment 190 across the 27 interventional studies, 1,300 across the 3 observational. Of the 14 that completed or were terminated, 2 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 30 have an industry lead sponsor. The 10 most frequent:
Istituto Oncologico Veneto IRCCS is the lead sponsor of 47 studies on the registry; 13 are open to participants now.
Istituto Oncologico Veneto IRCCS has 2 studies filed under Non-Muscle Invasive Bladder Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies in Non-Muscle Invasive Bladder Neoplasms with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06245603Istituto Oncologico Veneto IRCCSA Study to Evaluate Efficacy and Safety of Hydeal Cyst® Intravesical Instillations in Patients Treated With Intravesical Chemotherapy or Immunotherapy in Non-muscle Invasive Bladder Cancer | 2026-12 |
| NCT05614739Eli Lilly and CompanyFORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3 | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 30 studies in Non-Muscle Invasive Bladder Neoplasms with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
European Association of Urology (EAU) guidelines mandate a second transurethral resection of bladder tumour (re-TURBt) for patients with high-grade or pT1 non-muscle-invasive bladder cancer (NMIBC) to eradicate residual disease and avoid understaging. However, 30% to 50% or more of patients undergoing re-TURBt have no residual tumour found upon re-resection, incurring surgical and anaesthetic risks, potential morbidity, healthcare costs, and delays in adjuvant therapy without direct oncological benefit.
Current non-invasive triage tools, such as urine cytology and office cystoscopy, suffer from low sensitivity or diagnostic ambiguity due to ongoing post-operative inflammation and tissue healing in a recently resected bladder. While novel molecular biomarkers like Bladder EpiCheck® demonstrate high sensitivity and negative predictive value in the surveillance setting, single-timepoint measurements shortly after resection struggle to differentiate transient, healing-induced epigenetic changes from true persistent malignancy.
Evaluating the longitudinal trajectory of the EpiScore across two distinct post-operative timepoints (T1 and T2) provides a physiological basis for distinguishing decaying inflammatory/reparative signals from stable or rising signals indicative of residual disease. Demonstrating the diagnostic accuracy of Bladder EpiCheck® at T2, alongside the dynamic change in EpiScore (\ΔEpiScore), will establish whether non-invasive urine biomarker testing can reliably select low-risk pT1 NMIBC patients in whom re-TURBt can be safely omitted.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Bladder EpiCheck
The investigational IVD medical device evaluated as the index test is the Bladder EpiCheck® system (manufactured by Nucleix Ltd.; exclusive Italian distributor: A. Menarini Diagnostics s.r.l.). The assay is CE-IVD marked under Directive 98/79/EC (Annex III, General IVD category) and cleared by the US FDA via the 510(k) pathway. The manufacturer operates under a certified UNI CEI EN ISO 13485:2016 quality management system. Bladder EpiCheck® profiles the DNA methylation patterns of 15 proprietary DNA biomarkers on genomic DNA isolated from the cellular pellet of a voided urine sample. The assay protocol involves DNA extraction, digestion with a methylation-sensitive restriction enzyme, and subsequent multiplex real-time polymerase chain reaction (multiplex real-time PCR). Dedicated analysis software generates a quantitative integrative score termed the EpiScore, on a continuous scale from 0 to 100. In accordance with the manufacturer's Instructions for Use (IFU), the qualitative diagno
Diagnostic accuracy of Bladder EpiCheck® test at timepoint T2 for residual disease at second TURBt in T1 NMIBC patients.
Diagnostic accuracy of EpiScore at T2 (categorized as \> 60 positive vs ≤ 60 negative) evaluated against central histopathology review of the second TURBt, measured as Sensitivity, Specificity, Positive Predictive Value (PPV), Negative Predictive Value (NPV), Accuracy, and Likelihood Ratios.
Time frame: Through study completion, an average of 2 years
Diagnostic accuracy of change EpiScore between the two subsequent timepoints T1 and T2.
Average daily rate of change in EpiScore, calculated as ∆EpiScore=(T2-T1)/(Days between T1 and T2) evaluated against second TURBt residual disease status using a univariate logistic regression model and Area Under the ROC Curve (AUC) with 95% CI.
Time frame: Through study completion, an average of 2 years
Diagnostic accuracy of Bladder EpiCheck® test at timepoint T1
Sensitivity, Specificity, PPV, NPV, Accuracy, and Likelihood Ratios (95% CI) of EpiScore at T1 (\> 60 vs ≤ 60) for residual disease at second TURBt
Time frame: Through study completion, an average of 2 years
Diagnostic accuracy of urinary cytology at timepoints T1 and T2
Sensitivity, Specificity, PPV, NPV, Accuracy, and Likelihood Ratios (95% CI) of urinary cytology (Paris System classification) at T1 and T2 against second TURBt histopathology
Time frame: Through study completion, an average of 2 years
Agreement at T1 and T2 between Bladder EpiCheck® and urinary cytology
Concordance between Bladder EpiCheck® and urinary cytology at T1 and T2, quantified by Cohen's kappa (κ) coefficient.
Time frame: Through study completion, an average of 2 years
Agreement between T1 and T2 of Bladder EpiCheck®;
Agreement on paired aliquots of Bladder EpiCheck® between timepoints T1 and T2 with McNemar's test for paired data
Time frame: Through study completion, an average of 2 years
Agreement between T1 and T2 of urinary cytology
Agreement on paired aliquots of urinary cytology between timepoints T1 and T2 with McNemar's test for paired data
Time frame: Through study completion, an average of 2 years
Diagnostic accuracy at T1 and T2 of the combination of Bladder EpiCheck® and urinary cytology, defined in two versions: (1) as negative when both are negative, (2) as negative when at least one is negative
Sensitivity, Specificity, PPV, NPV, and Accuracy at T1 and T2 evaluated under two combination definitions: (1) negative when both tests are negative; (2) negative when at least one test is negative
Time frame: Through study completion, an average of 2 years
Diagnostic accuracy in the previous settings for predicting high-grade disease, ≥ pT1, and/or concomitant Carcinoma in Situ (CIS) at second TURBt;
Diagnostic accuracy measures (Sensitivity, Specificity, PPV, NPV) of tests and combinations specifically for predicting high-grade disease, ≥ pT1, and/or concomitant Carcinoma in Situ (CIS) at second TURBt
Time frame: Through study completion, an average of 2 years
Diagnostic accuracy of alternative definitions of change in EpiScore
Diagnostic accuracy and AUC for alternative definitions of Episcore change between T1 and T2: absolute difference (T2-T1) and relative percentage change (T2-T1)/T1;
Time frame: Through study completion, an average of 2 years
Change in positivity rate of Bladder EpiCheck® and urinary cytology between T1 and T2 among patients whose second TURBt is negative.
9\) Proportion of test positivity change between T1 and T2 in patients without residual disease (measuring the clearance rate of post-operative false positives).
Time frame: Through study completion, an average of 2 years
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Jan 2029, 24 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Non-Muscle Invasive Bladder Neoplasms →
Istituto Oncologico Veneto IRCCS